MRK - Merck wins FDA approval of sotatercept for rare lung disease
2024-03-26 17:48:09 ET
More on Merck
- Merck Phase 3 trial for Keytruda combo fails in lung cancer
- Merck hits main goal for Keytruda in late-stage trial for cervical cancer
- Merck & Co., Inc. (MRK) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
- Merck & Co., Inc. (MRK) Management presents at Leerink Partners 2024 Global Biopharma Conference (Transcript)
- Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript)